BAYER AKTIENGESELLSCHAFT «...678910...» Página 9 de 137 desde 01/07/1988 hasta 03/06/2024 21/09/2018 10:16 BAYER AKTIENGESELLSCHAFT R&D: new licenses, patents and registered trademarks Bayer’s Jivi® approved in Japan for hemophilia A Número de registro: 269794 13/09/2018 12:10 BAYER AKTIENGESELLSCHAFT Composition of the board of directors Stefan Oelrich to join Bayer Board of Management and head Pharmaceuticals Division Número de registro: 269531 05/09/2018 08:30 BAYER AKTIENGESELLSCHAFT Information on P&L Bayer AG: Public Information refered to Q2-2018 Número de registro: 269311 05/09/2018 07:50 BAYER AKTIENGESELLSCHAFT Transmissions and purchases of capital undertakings Bayer completes biggest acquisition in its history Número de registro: 269309 05/09/2018 07:42 BAYER AKTIENGESELLSCHAFT Information on P&L Bayer: Q2 2018 Analyst and Investor Briefing Número de registro: 269308 04/09/2018 14:42 BAYER AKTIENGESELLSCHAFT Transmissions and purchases of capital undertakings LEO Pharma closes acquisition of Bayer’s prescription dermatology business in the United States Número de registro: 269300 03/09/2018 16:47 BAYER AKTIENGESELLSCHAFT Legal disputes Brazilian court rules that growers will continue to have access to glyphosate Número de registro: 269280 30/08/2018 13:11 BAYER AKTIENGESELLSCHAFT R&D: new licenses, patents and registered trademarks Bayer receives US approval for modern hemophilia A treatment Jivi® with a step-wise prophylaxis dosing regimen Número de registro: 269231 30/08/2018 07:57 BAYER AKTIENGESELLSCHAFT Information on P&L Update: Bayer: Q2 2018 Publication Schedule Número de registro: 269211 27/08/2018 09:09 BAYER AKTIENGESELLSCHAFT R&D: new licenses, patents and registered trademarks Bayer submits European marketing authorization application for larotrectinib for the treatment of TRK fusion cancer Número de registro: 269150 Página 9 de 137 «...678910...»
